Last reviewed · How we verify
DLBS1033
DLBS1033, developed by Indonesia University, is a marketed small molecule with a key composition patent expiring in 2028. The drug's mechanism of interacting with biological systems to produce a therapeutic effect represents its core strength. The primary risk is the lack of disclosed revenue and key trial results, which may limit its competitive positioning.
At a glance
| Generic name | DLBS1033 |
|---|---|
| Also known as | Disolf, lumbrokinase |
| Sponsor | Indonesia University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Effect of Oral DLBS1033 in Patients With Diabetic Polyneuropathy (PHASE2,PHASE3)
- Oral DLBS1033 as Adjunctive Therapy in Acute Ischemic Stroke: Impact on Inflammatory Biomarkers and Outcomes (PHASE4)
- Comparing Oral Lumbrokinase DLBS1033 and Betahistine Mesylate in Benign Paroxysmal Positional Vertigo (PHASE4)
- DLBS1033 for Acute Ischemic Stroke Patients (PHASE2,PHASE3)
- Effect of DLBS1033 After Primary PCI in Patients With STE-ACS (PHASE2,PHASE3)
- The Benefit of Add On DLBS1033 for Ischemic Stroke Patient (PHASE2,PHASE3)
- DLBS1033 Treatment in Diabetic With Peripheral Arterial Disease (PHASE2,PHASE3)
- The Effects of DLBS1033 on Haemostasis Parameters in Healthy Volunteers (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DLBS1033 CI brief — competitive landscape report
- DLBS1033 updates RSS · CI watch RSS
- Indonesia University portfolio CI